Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Multiple Myeloma × Water × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pain 5 Colorectal Neoplasms 5 Neoplasms 4 Breast Neoplasms 4 Stomatitis 3 Neoplasm Metastasis 3 Adenoma 3 Urologic Neoplasms 2 Stomach Neoplasms 2 Mucositis 2 Insulin Resistance 2 Head and Neck Neoplasms 2 Vulvodynia 1 Urologic Diseases 1 Urolithiasis 1 Urinary Bladder Neoplasms 1 Urinary Bladder Diseases 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Sleep Initiation and Maintenance Disorders 1 Skin Neoplasms 1 Rectal Neoplasms 1 Polycystic Ovary Syndrome 1 Pain, Postoperative 1 Non-Muscle Invasive Bladder Neoplasms 1 Multiple Myeloma 1 Multiple Endocrine Neoplasia Type 1 1 Mobility Limitation 1 Melanoma 1 MRSA Colonization 1

Interventions

Dexamethasone 672 Bortezomib 378 Lenalidomide 361 Cyclophosphamide 288 Melphalan 218 Calcium Dobesilate 196 daratumumab 184 pomalidomide 161 carfilzomib 145 Thalidomide 103 fludarabine 100 fludarabine phosphate 96 Peripheral Blood Stem Cell Transplantation 95 Filgrastim 95 ixazomib 74 Granulocyte Colony-Stimulating Factor 69 Whole-Body Irradiation 68 dexamethasone acetate 66 Mycophenolic Acid 65 Busulfan 65 Tacrolimus 58 dexamethasone 21-phosphate 56 Prednisone 55 Cyclosporine 53 auricularum 52 isatuximab 51 elotuzumab 50 belantamab mafodotin 49 Antilymphocyte Serum 46 Etoposide 44

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00970021 2014-02-25

Agaricus Blazei Murill in Patients With Multiple Myeloma

Oslo University Hospital

Phase 2 Completed

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡